Mobile Diagnostics Without Compromise

The Challenges are Global

Clinicians need critical diagnostics earlier to empower the best, actionable care pathways.

The Value is Real

Empowered clinicians give millions the opportunity of timely treatment and improved patient outcomes.

Our Goal

Is to bring trusted diagnostics to the point of initial patient interaction, to expand access of quality healthcare to new settings, no matter where that patient interaction occurs

Nanomix Goals


Internal Link

Nanōmix Announces Granted CE Mark for eLab® S1 Assay Panel for Whole Blood Samples

We are very pleased to report CE mark designation in Europe for our S1 assay panel using a whole blood sample type

Internal Link

Nanōmix Announces Upgrade to OTCQB® Venture Market

Upgrading to the OTCQB is a timely and important milestone for Nanōmix, as we continue to commercialize our Nanōmix eLab® system, a mobile point-of-care diagnostic testing platform.

Internal Link

Nanōmix Receives CE Mark for its eLab COVID-19 Rapid Point-of-Care Antigen Panel

Receiving the CE mark for our COVID-19 rapid antigen test is a key milestone which further validates our rapid and accurate point-of-care (POC) testing technology.

Internal Link

Nanōmix Appoints Vidur Sahney as Chief Operating Officer

Relocates Headquarters and Labs to a Larger Facility while Reducing Overhead Expense.

Internal Link

Nanōmix Corporation Announces Securities Purchase Agreement with GHS Investments for up to $3.0 Million

GHS Investments, LLC (GHS) is a leading private investment and management group.

External Link

Nanōmix Announces Three new Customer and Distributor Congress locations and dates.

ECCMID in Portugal

Apr 23 - 26, 2022

AACC in Chicago

Jul 26 - 28, 2022

Medica in Dusseldorf

Nov 14 - 17, 2022